Keyhole limpet haemocyanin - Intracel

Drug Profile

Keyhole limpet haemocyanin - Intracel

Alternative Names: BCI-ImmuneActivator; Keyhole limpet hemocyanin; KLH

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intracel Corporation
  • Class Adjuvants; Antineoplastics; Blood proteins; Metalloproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Interstitial cystitis

Most Recent Events

  • 22 Feb 2007 No development reported - Phase-III for Bladder cancer in Europe (Intravesicular)
  • 22 Feb 2007 Phase-II clinical trials in Interstitial cystitis (unspecified route)
  • 22 Dec 2003 Mentor has terminated its licence for keyhole limpet haemocyanin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top